MWMeijuan Wu

Meijuan Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meijuan Wu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating lncRNAs in Cancer

    by Le Qu, Cheng Chen, Meijuan Wu, Yulin Zhou

    Circulating lncRNAs (noncoding RNAs of 200 nucleotides or more) have been proposed as a new class of potential biomarkers for cancer diagnosis and prognosis. Circulating lncRNAs seem more reliable than other circulating nucleic acids due to their high stability in the blood. In this chapter, we will describe the characteristics of circulating lncRNAs; summarize the role of circulating lncRNAs as potential biomarkers for cancer diagnosis and cancer prognosis, respectively, focusing on their sensitivity and specificity as biomarkers; provide recommendations for the detection of circulating lncRNA levels; and finally discuss challenges encountered.


  • Open Access

    Dysregulation of miR-6868-5p/FOXM1 circuit contributes to colorectal cancer angiogenesis

    by Ye Wang, Meijuan Wu, Zengjie Lei, Mengxi Huang, Zhiping Li, Liya Wang, Qijun Cao, Dong Han, Yue Chang, Yanyan Chen, et al.

    Transcription factor forkhead box M1 (FOXM1) is a crucial regulator in colorectal cancer (CRC) progression. However, the regulatory mechanisms causing dysregulation of FOXM1 in CRC remain unclear. Dual-luciferase reporter assay was conducted to determine FOXM1 as miR-6868-5p target. The function of miR-6868-5p and FOXM1 in CRC angiogenesis was verified in vitro. Intratumoral injection model was constructed to explore the effect of miR-6868-5p on angiogenesis in vivo. Chromatin immunoprecipitation assays were used to assess direct binding of H3K27me3 to the miR-6868 promoter. Through integrated analysis, we identified miR-6868-5p as the potent regulator of FOXM1. Overexpression of miR-6868-5p in CRC cells inhibited the angiogenic properties of co-cultured endothelial cells, whereas silencing of miR-6868-5p had opposite effects. In vivo delivery of miR-6868-5p blocked tumor angiogenesis in nude mice, resulting in tumor growth inhibition. Rescue of FOXM1 reversed the effect of miR-6868-5p on tumor angiogenesis. Further mechanistic study revealed that FOXM1 promoted the production of IL-8, which was responsible for the miR-6868-5p/FOXM1 axis-regulated angiogenesis. Reciprocally, FOXM1 inhibited miR-6868-5p expression through EZH2-mediated H3K27me3 on miR-6868-5p promoter, thus forming a feedback circuit. Clinically, the level of miR-6868-5p was downregulated in CRC tissues and inversely correlated with microvessel density as well as levels of FOXM1 and IL-8 in tumor specimens. Together, these data identify miR-6868-5p as a novel determinant of FOXM1 expression and establish a miR-6868-5p/FOXM1 regulatory circuit for CRC angiogenesis, providing potential target for CRC treatment.